

**Briefing on Potential Medical Isotope
Production Licensing Actions
Coquí RadioPharmaceuticals Corp.**

**Topic: *Coquí's current status
for the production of Mo-99.***

Carmen Irene Bigles, President/ CEO

May 11th Nuclear Regulatory Commission



Acronyms

- NRC – Nuclear Regulatory Commission
- Coquí - Coquí RadioPharmaceuticals Corp.
- MIPF - Medical Isotope Production Facility
- ER - Environmental Report
- Mo-99 - Molybdenum 99
- FDA – Food and Drug Administration
- GTRI – Global Threat Reduction Initiative
- LEU – Low Enriched Uranium



Coquí RadioPharmaceuticals Corp.



Coquí Commercial Domestic Producer

- **Supply Capacity**: 100% U.S. market
- **First Private Sector Producer**: Supply chain outages and decommissioning of existing reactors and the looming price increases assure transition of Mo-99 production from government to the private sector



- **Timing of Transition:** without proven technology, private sector commercial scale production in the U.S. could be delayed causing Mo-99 to be scarce in the U.S. together with substantial price and demand increases.



Coquí's Technology

- **Supporting GTRI with Proven LEU Technologies**: LEU reactor fuel and fission targets and radiochemical process, currently used in Australia, Argentina and South Africa
- **INVAP**: proven designs successfully executed worldwide.



- **FDA Approved Product:** Our end product is the same already approved by the FDA that is subsequently imported to the U.S. for patient use.
- **Capacity:** production design objective is 7,000 Six-Day Curies per Week and allows for maintenance and refueling downtime assuring stable supply.



Application Status

- March 15, 2010: Coquí submitted a Letter of Intent to the NRC indicating its intention of submitting an application to License the MIPF
- May 2010: Coquí submitted its first licensing strategy document to the NRC



- June 2010: Coquí submitted its second licensing strategy document to the NRC, which provided for the NRC staff's review a Safety and Licensing Plan for the technical portions of the application
- September 2010: The NRC responded to these submittals providing Coquí with important information on preparing its application



- October 2010: Coquí held its first public hearing at the NRC
- Currently: a sufficient amount of the technical portion of the application has already been prepared



Site Selection

- **Site and Location:** Thanks to the efforts of Enterprise Florida, and the University of Florida Foundation a site has been chosen, which has been offered to Coquí by the Foundation
- **NUREG 1537 Compliance**
- **Status:** Phase I ER completed.



Financing

- **Demand for Mo-99 = Price Increase:**

- continued increased worldwide demand
- production shortfalls
- scheduled decommissioning

- **Investment Situation:**

- price increments will benefit the investment situation of proven Mo-99 production



Status: Coquí RadioPharmaceuticals Corp. is engaged in negotiations with investors to finance the licensing and the construction of the MIPF. Enterprise Florida also provided Coquí with a tax and workforce incentive package to establish the facility.




Moving Forward

- Coquí would like to take this opportunity to thank the NRC staff
- We are already well underway preparing our application, we have located a site and our technology is proven
- Long pole in the tent is financing. Once we have that lined up:
 - We will eagerly complete our NRC submittal



Time Line Financing in Place



Coquí RadioPharmaceuticals Corp.

***Sustainable Design + Proven Technology
+ Finance = Saving Lives + Global Threat
Reduction = A Better World***

- Questions?

